TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of diabetes mellitus;~* Understanding of study and provision of written informed consent; and~* 18 years of age or older.~Exclusion Criteria:~* Persistent visual impairment in one or both eyes;~* History of macular edema or retinal vascular (vein or artery) occlusion;~* History of ocular injections, laser treatment of the retina, or intraocular surgery other than cataract surgery without complications;~* Subject is contraindicated for fundus photography (for example, has light sensitivity);~* Subject has contraindications for mydriatic medications or is unwilling or unable to dilate;~* Subject is currently enrolled in an interventional study of an investigational device or drug; or~* Subject has a condition or is in a situation which in the opinion of the Investigator, might confound study results, may interfere significantly with the subject's participation in the study, or may result in ungradable clinical reference standard photographs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment for Bile Duct Cancer in the Liver

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age\>18 years~* Histological or cytological diagnosis of cholangiocarcinoma~* Disease not amenable to surgery~* Predominant disease load in the liver (in case of extra-hepatic involvement, only patients with lymph nodes metastases are allowed)~* Naïve to locoregional or systemic treatment (but patients who develop recurrent disease after surgery are suitable)~* ECOG PS 0-1~* At least one measurable disease lesion according to RECIST v 1.1~* Life expectancy of 12 weeks or longer~* Adequate hematological, renal and hepatic function~* Platelet ≥100 x 109~* ANC ≥ 1.5 x 109~* Bilirubin ≤ 30µmol/L~* Albumin ≥ 30g/L~* ALT ≤ 3 ULN~* INR ≤ 1.5~* Serum creatinine ≤ 1.5 x ULN~Exclusion Criteria:~* Prior malignancy except cervical carcinoma-in-situ or treated basal cell carcinoma. Any cancers treated curatively \> 5 years prior to study entry are permitted.~* Patients with extra-hepatic disease other than regional lymph node metastases.~* Evidence of ascites or cirrhosis, as determined by clinical or radiologic assessment~* Biliary obstruction with no possibility of drainage~* Non-malignant disease that would render the patient unsuitable for treatment according to the protocol~* Prior treatment of chemotherapy for the cholangiocarcinoma~* Prior radiation therapy to the upper abdomen~* Complete thrombosis of the main portal vein~* Tumor volume \> 50% of the normal liver volume~* Allergy to non-ionic contrast agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SIRT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* histologically or cytologically documented inoperable, locally advanced ( stage III), metastatic (stage IV) or recurrent NSCLC other than squamous cell (tumors of mixed histology should be categorized by the predominant cell type);~* ECOG PS status 0-2;~* life expectancy \>= 12weeks;~* adequate renal, liver and hematological function.~Exclusion Criteria:~* mixed, non-small and small cell tumors, or mixed adenosquamous carcinomas with a predominant squamous component;~* hemoptysis (\>=1/2 teaspoon of bright red blood) in previous 3 months;~* evidence of tumor invading major blood vessels on imaging;~* evidence of CNS metastases, even if previously treated.~* major surgery (including open biopsy), significant traumatic injury within 28 days prior to enrolment, or anticipation of need for major surgery during study treatment;~* prior chemotherapy for stage IIIb/IV disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab + Chemotherapy (Type: EXPERIMENTAL): Participants with advanced or recurrent NSCLC will be administered bevacizumab infusions at a dose of 7.5 milligram per kilogram (mg/kg) or 15 mg/kg (investigator's choice) on Day 1 and then every 3 weeks, intravenously (IV) for a maximum of 6 cycles in combination with the standard of care NSCLC first-line chemotherapy in line with the licensed national prescribing information, during the treatment period. The initial dose of bevacizumab will be administered following chemotherapy; all subsequent doses could be given before or after chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Non-smokers (refrained from any tobacco or nicotine usage, including smokeless tobacco, nicotine patches, etc.) for at least 6 months prior to Day 1 of the study~2. Body Mass Index of 19 through 40 kg/m2~3. Participants must be willing to follow dietary restrictions~4. Females of childbearing potential (ie, not menopausal, no hysterectomy, no bilateral oophorectomy) must complete a negative pregnancy test (urine) prior to receiving any radioisotopes~5. No evidence of pelvic floor dysfunction~6. If clinically indicated, absence of an evacuation disorder should be confirmed within 30 days prior to the first dose of study medication~7. At Screening, patients must meet ROME III Criteria for FC, which assumes an absence of a structural or biochemical explanation~8. The patient's screening (baseline) colonic transit test must show a GC ≤ 2.4 at 24 hours; and~9. Baseline EKG shows QTc interval ≤ 450mSec~Exclusion Criteria:~1. History of clinically-significant manifestations or current abnormality of any organ system~2. History of inflammatory bowel disease~3. Any history of GI surgery within 6 months prior to the first dose of study medication~4. History of clinically-significant prolonged diarrhea, in the absence of a laxative~5. Patients who have started a special dietary habit and/or an intense physical workout program within 4 weeks prior to the first dose of study medication~6. Any clinically-significant surgical procedure within 30 days prior to the first dose of study medication~7. History of alcoholism or drug addiction within 12 months prior to the first dose of study medication~8. Any patient who has had an acute illness within 5 days prior to the first dose of study medication, eg, flu syndrome, GI virus, indigestion~9. Patients who are breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Capsule (Type: PLACEBO_COMPARATOR): Placebo Capsules
- YKP10811 Drug Product Capsule, 10 mg (Type: ACTIVE_COMPARATOR): None
- YKP10811 Drug Product Capsule, 20 mg (Type: ACTIVE_COMPARATOR): None
- YKP10811 Drug Product Capsule, 30 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Infants 6 weeks of age (range: 42-48 days).~* Parents that consent for participation in the full length of the study.~* Parents that are able to understand and comply with planned study procedures.~Exclusion Criteria:~* Parents and infants who are unable to participate in the full length of the study.~* Evidence of a chronic medical condition identified during physical exam.~* A diagnosis or suspicion of immunodeficiency disorder either in the infant or in an immediate family member.~* A diagnosis or suspicion of bleeding disorder that would contraindicate parenteral administration of IPV or collection of blood by venipuncture.~* Acute diarrhea, infection or illness at the time of enrollment (6 weeks of age) that would require infant's admission to a hospital or would contraindicate provision of OPV or IPV per country guidelines.~* Acute vomiting and intolerance to liquids within 24 hours before the enrollment visit (6 weeks of age).~* Receipt of any polio vaccine (OPV or IPV) before enrollment based upon documentation or parental recall.~* Known allergy/sensitivity or reaction to polio vaccine or contents of polio vaccine.~* Infants from multiple births. Infants from multiple births will be excluded to reduce the potential for contact transmission of vaccine poliovirus to siblings. The infant(s) from a multiple birth who is/are not enrolled would be likely to receive routine immunization and transmit vaccine poliovirus to the enrolled infant.~* Infants from premature births (\<37 weeks of gestation).

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 7 Weeks
- Healthy Volunteers: t

Study Arms:
- mOPV2 at 6 and 7 weeks of age (Type: ACTIVE_COMPARATOR): Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 7 weeks of age
- mOPV2 at 6 and 8 weeks of age (Type: ACTIVE_COMPARATOR): Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 8 weeks of age
- mOPV2 at 6 and 10 weeks of age (Type: ACTIVE_COMPARATOR): Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 10 weeks of age
- mOPV2 at 6 and 10 week of age and IPV at 6 weeks of age (Type: ACTIVE_COMPARATOR): Participants enrolled in this arm would receive a dose monovalent type 2 oral polio vaccine (mOPV2) at 6 and 10 weeks of age. In addition, the participants will also receive inactivated polio vaccine (IPV) at 6 weeks of age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Wisconsin Tobacco Quit Line Medicaid Incentive Evaluation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* enrollment in Wisconsin Medicaid (BadgerCare Plus)~* resides in study area (one of 25 counties)~* 18 or older~* English or Spanish speaking~* has smoked daily (at least 5 cigarettes each day) over the last week~* willingness to attend visits at his/her PCC (primary care clinic) or go to a testing site at baseline and 6 months (2 times over a 6 month period), provide urine samples or participate in exhaled carbon monoxide testing, and complete follow-up phone calls from the WTQL~* willingness to inform the WTQL as to any change in address, phone number, clinic attended, or health plan.~Exclusion Criteria:~* not enrolled in Wisconsin Medicaid (BadgerCare Plus)~* not reside in study area~* less than 18 years of age~* not English or Spanish speaking~* does not smoke daily (at least 5 cigarettes each day) over the last week~* not willing to attend visits at his/her PCC (primary care clinic) or alternative testing site at baseline and 6 months (2 times over a 6 month period), provide urine or exhaled carbon monoxide samples, and complete follow-up phone calls.~* not willing to inform the WTQL as to any change in address, phone number, clinic attended, or health plan.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Counseling from WTQL
- Incentive (Type: EXPERIMENTAL): Counseling from WTQL; Financial incentive to participate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects between 50 to 75 years of age~2. Scheduled THA~3. ASA Score ≤ 3~4. Signed written informed consent~Exclusion Criteria:~1. Muscle diseases~2. Severe neurological diseases~3. Opioid long term medication~4. Pain chronification \> stadium II of Gerbershagen~5. Immunosuppression due to illness or medication~6. Ankylosing spondylitis~7. History of ectopic bone formation of any localisation~8. Exclusion criteria for MRI (pace maker, defibrillator, ferromagnetic intracerebral clips)~9. Uncontrolled hypertension (defined as diastolic blood pressure \> 100 mmHg or systolic blood pressure \> 200 mmHg during screening)~10. Life-threatening ventricular arrhythmia or unstable angina - characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, and prolonged~11. ST segment elevation myocardial infarction and/or TIA/CVA within three (3) months prior to enrollment. Subjects with severe congestive heart failure symptoms (i.e. NYHA Stage IV)~12. Subject has malignancy undergoing treatment including chemotherapy, radiotherapy or immunotherapy~13. Body Mass Index (BMI) of 35 Kg/m2 or greater~14. Known allergies to protein products (horse or bovine serum, or porcine trypsin) used in the cell production process~15. Known HIV, syphilis at time of screening~16. Known active Hepatitis B, or Hepatitis C infection at the time of screening~17. Pregnant or breast-feeding women or women of childbearing potential not protected by an effective contraceptive method of birth control (defined as pearl index \< 1)~18. In the opinion of the investigator, the subject is unsuitable for cellular therapy~19. Subject is currently enrolled in, or has not yet completed a period of at least 30 days since ending other investigational device or drug trial(s)~20. Subjects who are legally detained in an official institute

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 150M PLX-PAD (Type: EXPERIMENTAL): Single course, multiple IM injections
- 300M PLX-PAD (Type: EXPERIMENTAL): Single course, multiple IM injections
- Placebo (Type: PLACEBO_COMPARATOR): Single course, multiple IM injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current or former cigarette smokers with a cigarette smoking history of at least 10 pack-years~* A diagnosis of stable moderate to severe COPD and stable airway obstruction as defined by the Global Initiative for Chronic Obstructive Lung Disease guidelines and stable airway obstruction.~Exclusion Criteria:~* Patients who have been hospitalized for an acute COPD exacerbation within three months prior to Visit 1~* Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the six weeks before Visit 1.~* Patients with any clinically significant respiratory conditions other than COPD~* Clinical history that suggests that the patient has asthma as opposed to COPD~* Chronic use of oxygen therapy ≥ 15 hours/day~* Patients with clinically significant cardiovascular conditions~* Patients with uncontrolled infection that may place the patient at risk resulting from human immunodeficiency virus (HIV), active hepatitis and/or patients with diagnosed active tuberculosis~* Patients with a history of hypersensitivity reaction to inhaled anticholinergics,~* Patients with Stage II hypertension, defined as systolic pressure of 160 and above, and/or diastolic pressure of 100 and above~* Current diagnosis of cancer other than basal or squamous cell skin cancer

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg fixed dose combination (FDC), high dose twice per day
- 2 (Type: ACTIVE_COMPARATOR): Inhaled formoterol fumarate 12 μg, twice per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-positive~* 18 years of age or older~* Self-identified as African American/Black~* Been prescribed antiretroviral therapy (ART) in the past 12 months~* Self-reported adherence problems (i.e. missed at least 1 ART dose in the past month) and/or detectable viral load~* Willing to use Medication Events Monitoring System (MEMS) for electronic adherence monitoring.~Exclusion Criteria:~* HIV-negative~* 17 years of age or younger~* Not self-identified as African American/Black, not on antiretroviral therapy (ART) or not prescribed ART therapy in the last than 12 months~* No self-reported adherence problems and/or no detectable viral load~* Not willing to use Medication Events Monitoring System (MEMS) for electronic adherence monitoring.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rise - Treatment Education (Type: EXPERIMENTAL): Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if \<85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
- Control - No Treatment Education (Type: NO_INTERVENTION): The Usual Care control group will only receive standard of care through their HIV clinics.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is at least 18 years of age but no more than 70 years of age.~* Subject has at least two non-adjacent teeth in contralateral quadrants of the same jaw with an insufficient zone (\< or = 1mm) of attached gingiva that requires soft tissue grafting. (1-3 teeth may be treated. In case of adjacent teeth requiring grafting, only one tooth at each site will act as test or control tooth, but all teeth will get the same treatment).~* Root coverage is not desired at the time of grafting.~* Females of childbearing potential must have a documented negative urine pregnancy test.~* Subjects must have read, understood and signed an institutional review board (IRB) approved Informed Consent Form.~* Subjects must be able and willing to follow study procedures and instructions.~Exclusion Criteria:~* Subject with class III recession in the presence of a shallow vestibule or class IV recession.~* Subject with vestibule depth of less than 7mm from base of recession.~* Subject with any systemic conditions that could compromise wound healing and preclude periodontal surgery (i.e., diabetes mellitus, cancer, human immunodeficiency virus (HIV), bone metabolic diseases).~* Subject who is currently receiving or has received within two months prior to study entry, systemic corticosteroids, immunosuppressive agents, radiation therapy, and/or chemotherapy which could compromise wound healing and preclude periodontal surgery.~* Subject with the presence of acute infectious lesions in the areas intended for surgery.~* Subject who has used any tobacco product within 3 months.~* Subject who is taking intramuscular or intravenous bisphosphonates.~* Subject with only molar teeth suitable for soft tissue grafting.~* Subject with teeth that have Miller Grade 2 or higher mobility.~* Subject with known hypersensitivity to bovine collagen and/or iodine (shellfish allergy).~* Subject who has received an investigational drug or biological/bioactive treatment within 30 days prior to study enrollment (medical or dental).~* Subject who was previously treated with Gintuit, Dermagraft or any other skin graft at the target site(s) or immediately adjacent teeth.~* Subject, who in the opinion of the investigator, for any reason other than those listed above, will not be able to complete the study per protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Within-subject design: one side of the mouth receives Gintuit
- 2 (Type: ACTIVE_COMPARATOR): Within-subject control: one side of mouth receives tissue harvested from the palate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete